Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 14/20 | 0.77 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.77 |
| ▸ | NQO2 | P16083 | 3/20 | 0.77 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.67 |
| ▸ | BLM | P54132 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | IDO1 | P14902 | 1/20 | 0.67 |
| ▸ | SPR | P35270 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.63 |
| ▸ | MPO | P05164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766265 | 0.91 | MTNR1A (0.82) | MTNR1AMTNR1BCYP1A2NQO2NOTUM | |
| SCHEMBL4655625 | 0.87 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2NQO2NOTUM | |
| SCHEMBL29766820 | 0.87 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2NQO2NOTUM | |
| Water SCHEMBL10579379 | 0.86 | KDM4E (0.60) | MTNR1AMTNR1BCYP1A2NQO2NOTUM | |
| SCHEMBL31543669 | 0.86 | MTNR1A (0.74) | MTNR1AMTNR1BCYP1A2NQO2NOTUM | |
| SCHEMBL10578553 | 0.84 | HTR1D (0.61) | MTNR1AMTNR1BCYP1A2NQO2NOTUM | |
| SCHEMBL10578549 | 0.84 | MTNR1A (0.56) | MTNR1AMTNR1BCYP1A2NQO2NOTUM | |
| SCHEMBL6765265 | 0.83 | HTR1A (0.64) | MTNR1AMTNR1BCYP1A2NQO2NOTUM | |
| SCHEMBL7015652 | 0.82 | MTNR1A (0.74) | MTNR1AMTNR1BCYP1A2NQO2NOTUM | |
| SCHEMBL6763965 | 0.82 | MTNR1A (0.74) | MTNR1AMTNR1BCYP1A2NQO2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730707-B2 | SUCH AS 5-(METHOXYCARBONYLAMINO)-N-ACETYLTRYPTAMINE; TREATING OCULAR HYPERTENSION, VARIOUS FORMS OF GLAUCOMA | INSPIRE PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| EP-1307191-A2 | USE OF INDOLE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRACULAR PRESSURE | Inspire Pharmaceuticals, Inc. (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2002-03-28 | — | — | US | claimed |
| WO-2002009702-A2 | USE OF INDOLE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRACULAR PRESSURE | INSPIRE PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | claimed |
| US-20040198803-A1 | Such as 5-(methoxycarbonylamino)-N - acetyltryptamine; therapy for ocular hypertension; vision defects | PINTOR JESUS J (ES) | 2004-10-07 | — | — | US | disclosed |
| US-6730707-B2 | SUCH AS 5-(METHOXYCARBONYLAMINO)-N-ACETYLTRYPTAMINE; TREATING OCULAR HYPERTENSION, VARIOUS FORMS OF GLAUCOMA | INSPIRE PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| EP-1307191-A2 | USE OF INDOLE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRACULAR PRESSURE | Inspire Pharmaceuticals, Inc. (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2002-03-28 | — | — | US | disclosed |
| WO-2002009702-A2 | USE OF INDOLE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR REDUCING INTRACULAR PRESSURE | INSPIRE PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198803-A1 | Such as 5-(methoxycarbonylamino)-N - acetyltryptamine; therapy for ocular hypertension; vision defects | MTNR1A, MTNR1B, MC5R | MTNR1A 1/4885MTNR1B 2/4885CYP1A2 1334/4885 |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | MTNR1A, MTNR1B, MC5R | MTNR1A 1/4885MTNR1B 2/4885CYP1A2 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.